Neovasc to Report First Quarter Financial Results on May 12, 2022
Neovasc Inc. (NVCN) will report its financial results for Q1 2022 on May 12, 2022. The call will feature CEO Fred Colen and CFO Chris Clark, starting at 4:30 PM EDT. Participants can join via phone or webcast, with the replay available shortly after. Neovasc develops specialty medical devices for cardiovascular treatment, notably the Reducer for refractory angina, available in Europe since 2015, and Tiara™ for mitral valve disease, currently under clinical investigation.
- None.
- None.
VANCOUVER and MINNEAPOLIS, MN, April 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ , TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company’s results at 4:30 pm EDT on May 12, 2022.
Interested parties may access the conference call by dialing (877) 407-9208 or (201) 493-6784 (International) and reference Conference ID 13729200. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words expect, anticipate, estimate, may, will, should, intend, believe, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the Risk Factors section of the Company’s Annual Report on Form 20-F and in the Managements Discussion and Analysis for the year ended December 31, 2021 (copies of which may be obtained at www.sedar.com or www.sec.gov ). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Email: Sean.Leous@icrinc.com
FAQ
When will Neovasc report its Q1 2022 financial results?
Who will host the Neovasc conference call on May 12, 2022?
How can I access the Neovasc conference call?
What products does Neovasc develop for cardiovascular treatment?
